← Back to Search

Personal Amplifier for Hearing Loss (HearVA-ED Trial)

N/A
Recruiting
Led By Joshua Chodosh, MD MSHS
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Inability to consent to participate in research
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-5 days after initial ed stay
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if giving personal amplifiers to Veterans with hearing difficulties in emergency departments can help them hear better and understand medical instructions. The study aims to see if this can reduce their need to return to the emergency department shortly after their visit. If successful, this simple solution could be used widely in VA emergency departments across the country.

Who is the study for?
This trial is for Veterans with hearing difficulties who can consent to research, speak English or Spanish, and have a medium to low emergency severity index. It's not for those with high acuity emergencies, cochlear implants, or minimal hearing issues as per the Hearing Handicap Inventory-Screen.
What is being tested?
The study tests if personal amplifiers help Veteran patients in emergency departments hear better and understand discharge instructions more clearly, potentially reducing quick return visits. The program's feasibility when run by ED staff will also be assessed.
What are the potential side effects?
Since this trial involves non-invasive interventions like personal amplifiers rather than medications or surgeries, significant side effects are not anticipated.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am unable to give consent for research participation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-5 days after initial ed stay
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-5 days after initial ed stay for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
ED 3-day Readmissions
Secondary study objectives
ED 30-day Readmissions
Patient-Rated Quality of Hearing, Understanding, and Communication With Providers During ED Stay
Patient-Rated Quality of Post-Discharge Care
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Intervention: Personal AmplifierExperimental Treatment1 Intervention
Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
Group II: Control: No Personal AmplifierExperimental Treatment1 Intervention
Consenting participants will be randomly assigned to the control group while receiving care in the emergency department

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Personal amplifiers work by increasing the volume of sound, making it easier for individuals with hearing loss to hear and understand speech and environmental noises. This is particularly beneficial in settings where clear communication is essential, such as in emergency departments, to ensure patients understand discharge instructions and reduce the risk of readmission. Other common treatments for hearing loss include hearing aids, which amplify sound and improve speech clarity, and cochlear implants, which bypass damaged parts of the ear and directly stimulate the auditory nerve. These treatments are crucial for improving the quality of life and daily functioning of individuals with hearing loss.
[Biological therapies in otology. German version].The CD2 isoform of protocadherin-15 is an essential component of the tip-link complex in mature auditory hair cells.Technologic advances in aural rehabilitation: applications and innovative methods of service delivery.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,668 Previous Clinical Trials
3,764,816 Total Patients Enrolled
15 Trials studying Hearing Loss
1,998 Patients Enrolled for Hearing Loss
New York University Grossman School of MedicineUNKNOWN
NYU Langone HealthOTHER
1,415 Previous Clinical Trials
855,153 Total Patients Enrolled
16 Trials studying Hearing Loss
1,154 Patients Enrolled for Hearing Loss
Joshua Chodosh, MD MSHSPrincipal InvestigatorManhattan Campus of the VA NY Harbor Healthcare System, New York, NY
1 Previous Clinical Trials
133 Total Patients Enrolled
1 Trials studying Hearing Loss
133 Patients Enrolled for Hearing Loss

Media Library

Personal Amplifier Clinical Trial Eligibility Overview. Trial Name: NCT05028972 — N/A
Hearing Loss Research Study Groups: Control: No Personal Amplifier, Intervention: Personal Amplifier
Hearing Loss Clinical Trial 2023: Personal Amplifier Highlights & Side Effects. Trial Name: NCT05028972 — N/A
Personal Amplifier 2023 Treatment Timeline for Medical Study. Trial Name: NCT05028972 — N/A
Hearing Loss Patient Testimony for trial: Trial Name: NCT05028972 — N/A
~262 spots leftby Dec 2025